
    
      In addition to the 5-year analysis conducted in September 2003, two other analyses were
      planned when 590 and 700 Disease Free Survival events occurred. However, due to the lower
      than predicted DFS event rate, and in agreement with FDA and EMA, a time-based final analysis
      at 10 years was considered more appropriate than an event-based (700 Disease Free Survival
      events) analysis.
    
  